Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for cedar fever sufferers: drug eases severe allergy symptoms

NCT ID NCT03369704

Completed Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called omalizumab in 337 adults and teens with severe Japanese cedar pollen allergy (hay fever) that standard medicines couldn't control. Participants received either omalizumab or a placebo on top of their usual allergy treatments for 12 weeks. The goal was to see if the drug could better relieve nasal and eye symptoms during the worst part of the pollen season.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEASONAL ALLERGIC RHINITIS

Contacts and locations

Locations

  • Novartis Investigative Site

    Chiba, Chiba, 262-0015, Japan

  • Novartis Investigative Site

    Ichikawa, Chiba, 272-0143, Japan

  • Novartis Investigative Site

    Kashiwa, Chiba, 2270082, Japan

  • Novartis Investigative Site

    Matsudo, Chiba, 270-0034, Japan

  • Novartis Investigative Site

    Matsudo, Chiba, 2710077, Japan

  • Novartis Investigative Site

    Urayasu, Chiba, 279-0012, Japan

  • Novartis Investigative Site

    Kawasaki, Kanagawa, 212-0027, Japan

  • Novartis Investigative Site

    Kawasaki, Kanagawa, 216 0006, Japan

  • Novartis Investigative Site

    Kawasaki, Kanagawa, 216-0002, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan

  • Novartis Investigative Site

    Koshigaya, Saitama, 343-0031, Japan

  • Novartis Investigative Site

    Arakawa-ku, Tokyo, 116 0011, Japan

  • Novartis Investigative Site

    Chiyoda-ku, Tokyo, 101-0063, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 103 0027, Japan

  • Novartis Investigative Site

    Edogawa-ku, Tokyo, 132-0014, Japan

  • Novartis Investigative Site

    Katsushika-ku, Tokyo, 125-0061, Japan

  • Novartis Investigative Site

    Nakano-ku, Tokyo, 164-0012, Japan

  • Novartis Investigative Site

    Setagaya-ku, Tokyo, 158-0097, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0008, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 160-0017, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site

    Toshima-Ku, Tokyo, 170-0005, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.